OncoMed
OncoMed initiates Phase Ib immuno-oncology combination clinical trial
March 18, 2016Medical Communications, Research and Development Merck, OncoMed, clinical trial, demcizumab, immuno-oncology, immuno-oncology combination, pembrolizumab, phase ib
OncoMed (NASDAQ: OMED) has announced the beginning of its Phase Ib clinical trial to investigate if the combination of demcizumab …
Celgene signs $177 million OncoMed deal
December 4, 2013Research and Development, Sales and Marketing Cancer, Celgene, OncoMed, stem cell
Celgene Corporation is paying OncoMed Pharmaceuticals $177.25 million to get access to its pipeline as part of a deal to …
Anti-cancer stem cell drug starts clinical trials
January 14, 2011Research and Development Cancer, GSK, GlaxoSmithKline, OMP-21M18, OMP-59R5, OncoMed, Stem cells, advanced solid tumour cancers
OncoMed and GSK’s novel anti cancer stem cell drug OMP-59R5 has begun clinical trials and could represent the future direction …
Bayer signs cancer stem cell research deal
June 18, 2010Research and Development Bayer Schering Pharma, Cancer, OncoMed, Stem cells
Bayer Schering Pharma has teamed up with a US oncology specialist to develop novel antibodies, protein therapeutics and small molecules …
Latest content
Migraine annual economic and quality-of-life burden in UK
October 1, 2026
bit.bio expands human heart cell portfolio through myriamed partnership
September 30, 2026
Phoenix Labs acquires Kent Pharma
September 29, 2026
Astoriom acquires Sampled’s UK stability storage operations
September 28, 2026
